Entropy Neurodynamics

Entropy Neurodynamics EBITDA Margin

The EBITDA Margin of Entropy Neurodynamics (ENP.AX) as of Nov 22, 2026 is -432.01 %. In the previous year, EBITDA Margin was -443.05 % — a change of -2.49% (higher).

EBITDA Margin

-432.01 %

YoY

-2.49%

Last updated:

EBITDA Margin of Entropy Neurodynamics is 2025 -432.01 % . EBITDA Margin of Entropy Neurodynamics was 2024 -443.05 % . It decreases by -2.49% higher compared to the previous year.

The Entropy Neurodynamics EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2022
-12,417.65 AUD
Jan 1, 2023
-1,275.55 AUD
Jan 1, 2024
-443.05 AUD
Jan 1, 2025
-432.01 AUD
The Entropy Neurodynamics EBITDA Margin history
YEAREBITDA MarginYoY
-432.01 %-2.49%
-443.05 %-65.27%
-1,275.55 %-89.73%
-12,417.65 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entropy Neurodynamics Stock analysis

What does Entropy Neurodynamics do? Entropy Neurodynamics Ltd develops and commercializes exosomes as therapeutic agents. The company holds intellectual property related to exosome technology and offers LEAP manufacturing, LOAD API loading, and EVPS tropism technologies. Pharmaceutical and biotechnology companies purchase these proprietary technologies to enhance their own exosome-based products. The firm invests in biopharmaceutical drug development and leverages its portfolio of know-how to support partners in exosome medicine development. Exopharm Ltd. is the company's brand name, and it operates through its exosome technology portfolio. The firm's technologies solve key challenges in exosome medicine success, including manufacturing efficiency and targeted delivery. Biopharmaceutical companies are the primary buyers of these technologies, seeking to integrate exosome delivery systems into their therapeutic pipelines. The company's business model centers on licensing its exosome-related IP and know-how to pharmaceutical and biotech firms. By providing LEAP, LOAD API, and EVPS technologies, Entropy Neurodynamics enables partners to overcome technical barriers in exosome-based drug development. This approach generates revenue through technology licensing agreements with industry partners. Entropy Neurodynamics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entropy Neurodynamics stock

EBITDA Margin of Entropy Neurodynamics is -432.01 % in 2025.

EBITDA Margin of Entropy Neurodynamics changed from -443.05 % to -432.01 %, representing a -2.49% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Entropy Neurodynamics since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Entropy Neurodynamics with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Entropy Neurodynamics

All Key Metrics — Entropy Neurodynamics